logo-loader
viewOrgenesis

Orgenesis launches research collaboration with Madrid hospital to establish point-of-care center

The hospital will rely on Orgenesis’ biotech platform to develop and manufacture cell and gene therapies

Madrid, Spain
Orgenesis' POCare technology enables hospitals to develop and supply CGTs for patients by combining proprietary knowledge with automated, closed technology to process cell therapies at each point-of-care site

Orgenesis Inc (NADAQ:ORGS) announced a research and development collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, which will establish a point-of-care center utilizing its POCare platform.

The hospital will rely on Orgenesis’ biotech platform to develop and manufacture cell and gene therapies (CGTs). The company’s POCare technology enables hospitals to develop and supply CGTs for patients by combining proprietary knowledge with automated, closed technology to process cell therapies at each point-of-care site.

"Hospital Infantil Universitario Niño Jesús will be an amazing addition to our POCare Network,” Orgenesis CEO Vered Caplan said in a statement. “We believe that our POCare Technologies will enable the hospital to advance this new therapy for the treatment of solid metastatic tumors based on oncolytic virotherapy."

READ: Orgenesis unveils plans to repurchase up to $10 million in stock

The first collaboration involves the clinical development and validation of T-cell and dendritic cell-based therapies, the company said. Once that project is successfully completed, the parties plan to develop the hospital's oncolytic-based cell therapy technology, Celyvir.

Celyvir represents a new strategy for the treatment of solid metastatic tumors based on oncolytic virotherapy administered by mesenchymal cells obtained from bone marrow.

"We look forward to collaborating with Orgenesis in order to develop our oncolytic based cell therapy,” said Manuel Ramírez, head of the pediatric advanced therapies unit at Hospital Infantil Universitario Niño Jesús.

“By utilizing Orgenesis' CGT Biotech Platform, we seek to reduce the cost of bringing our technology to market, enabling others to use it in their patients, assuring high quality standards by integrating Orgenesis' proprietary POCare Technologies."

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 7.26 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $159.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read